2024-515109-24-00RecruitingPhase 3
Measuring Oncological Value of Exercise and Statin (MOVES)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 21 May 2026
Brief summary (registry, in English)
1) Whether supervised group exercise with aerobic and resistance training during anticancer therapy improves the efficacy of anticancer therapy in advanced breast, renal, ovarian, and prostate cancer compared with self-administered exercise and whether the use of atorvastatin combined with supervised group exercise further improves the response to cancer treatment.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- First submitted
- 6 Aug 2024
- Start date
- 31 Mar 2023
- Lead sponsor
- Pirkanmaan hyvinvointialue
- EU CT number
- 2024-515109-24-00
- EudraCT number
- 2019-001982-34
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 240
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic prostate, breast, ovarian or kidney cancer who are about to start their first anticancer treatment. It studies exercise, with or without atorvastatin.
- Age
- 18 years or older
- Sex
- Men and women can join. Breast and ovarian cancer: women. Prostate cancer: men. Kidney cancer: women and men.
- Disease stage
- Metastatic prostate, breast, ovarian or kidney cancer, confirmed by tissue examination and imaging.
- Earlier treatment
- 1st line anticancer therapy is being started. Patients not on statins at the start cannot be taking cholesterol-lowering drugs.
Main reasons for not taking part
- High fracture risk
- Unable to exercise and/or unable to receive anticancer therapy
- Severe liver or kidney failure
- Pregnant or breastfeeding women, and minors
- Not on statins at the start: current cholesterol-lowering drugs, serious side effects from them in the past, or drugs that interact with atorvastatin
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- All patients: 1. High fracture risk 2. Unable to exercise and/or unable to receive anticancer therapy 3. Psychologically uncooperative 4. Severe liver or kidney failure 5. Special category of subjects under the Medical Research Act (1999/488) (e.g. minors and pregnant or breastfeeding women). In addition to excl. criteria for patients who were not on statin medication at the start of the study: Active use of cholesterol-lowering drugs, A history of serious side effects from cholesterol-lowering drugs and Continued use of drugs that interact with atorvastatin during the period of the study
Who the study is looking for
- Patients with histologically and imaging confirmed metastatic prostate, breast, ovarian or renal cancer for which 1st line anticancer therapy is being initiated. 2) The patient consents to the study and signs a written informed consent. 3) Women (breast, ovarian and renal cancer) and men (prostate and renal cancer) of legal age (18 years =>) are recruited. 4) Women will use a reliable method of contraception during the trial.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pirkanmaan hyvinvointialue | Tampere | Finland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.